Medicskin Holdings Ltd (8307) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Medicskin Holdings Ltd HK$0.05, price HK$0.14, upside -64.0%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Medicskin Holdings Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range HK$0.0920 – HK$0.3500 · fair‑value band HK$0.0400 – HK$0.0600 · the HK$0.1390 price screens above the HK$0.0500 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Medicskin Holdings in your weekly email
Every Wednesday you see whether Medicskin Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Medicskin Holdings Limited, an investment holding company, provides medical skin care services in Hong Kong.
Show more
Medicskin Holdings Limited, an investment holding company, provides medical skin care services in Hong Kong. The company operates Medicskin centers, which provides various medical skin care services for the treatment of skin diseases and problems, such as acne, pigmentation, rosacea, dermatitis, eczema, and warts, as well as improvement of appearance through inter alia, skin rejuvenation, facial sculpturing, and body contouring treatments; and treatment of acne scars and enlarged pores, removal of undesirable naevi, and hair removal. It provides medical consultancy services. In addition, the company engages in the sale of skincare products. Further, it provides health management services; prescription and dispensing services of pharmaceutical products, medicines, and skincare products; and non-invasive/minimally invasive treatment services. Medicskin Holdings Limited was founded in 2000 and is headquartered in Sheung Wan, Hong Kong. Medicskin Holdings Limited is a subsidiary of Topline Worldwide Limited.
Stock analysis
Medicskin Holdings Ltd (8307) currently trades at HK$0.1390, while our model-based Fair Value estimate is HK$0.0500, 64.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$0.1300 per share, and 6 of the 22 models we run sit above the HK$0.1390 price.
Bear case: the Asset-Based group reads lowest at HK$0.0100, and 16 of the 22 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$0.0400 (bear) to HK$0.0600 (bull), the price of HK$0.1390 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Medicskin Holdings Ltd reported revenue of HK$47.9M in FY2026 versus HK$49.1M in FY2022, a compound −0.7%/yr. Reported net income was HK$936K in FY2026, compounding −30.1%/yr from FY2022.
Key figures
Market cap HK$69.8M (≈ $8.9M) · P/S ratio 1.45 · Net margin 2.0% · Return on equity 19.9% · Return on assets (EBIT) 4.1% · Operating margin 3.2% · Revenue (TTM) HK$48.2M · Revenue growth (YoY) +8.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 36% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside, at −64%, 8307 screens richer than that median.
Fair Value models
Bear HK$0.0400Fair Value HK$0.0500Bull HK$0.0600
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.69/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
Start year 2021 (pandemic). Over 10 years: −2.2% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−17.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−17.2%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−17.2% vs −10.7%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−6% → 1%
Start year 2021 (pandemic)
⚠ Revenue per share shrinking 4.4%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−6.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about −8.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside−64.0% · Bottom 25%
Profitability
Return on equity (TTM)19.9% · Top 25%
Return on assets0.8% · Bottom 25%
Net margin (TTM)1.9% · Below median
Operating margin (TTM)3.2% · Bottom 25%
Growth and dividend
Revenue growth8.0% · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/B1.70× · Cheaper than median
P/S (TTM)0.19× · Cheapest 25%
P/FCF2.0× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)40· sector 26
PAST (return on equity)79· sector 30
HEALTH (low debt)0· sector 89
DIVIDEND (yield)0· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Medicskin Holdings Ltd (8307) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$0.0500 versus a price of HK$0.1390, about −64% upside (overvalued).
What is the fair value of 8307?
Our model-based fair value for Medicskin Holdings Ltd is HK$0.0500 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.1390.
What is the quality score of 8307?
Medicskin Holdings Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medicskin Holdings Ltd (8307)?
Our model-based price target is the fair value of HK$0.0500 (as of Sep 27, 2026) from 22 valuation models. Cautious scenario HK$0.0400, optimistic scenario HK$0.0600. It is a calculation from audited fundamentals, not an analyst target.
What is the Medicskin Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$0.0500, about −64% upside versus a price of HK$0.1390 (overvalued). Cautious scenario HK$0.0400, optimistic scenario HK$0.0600. The calculation is refreshed regularly with new filings.
What is the revenue of Medicskin Holdings Ltd (8307)?
Medicskin Holdings Ltd reported trailing-twelve-month revenue of about HK$48.2M (latest available figure, as of Sep 27, 2026).
What growth is priced into Medicskin Holdings Ltd (8307)?
For today's price to be fair in a discounted-cash-flow model, Medicskin Holdings Ltd would have to grow free cash flow by -6.8 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.8 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 8307 use?
Our models discount Medicskin Holdings Ltd at 10.3 %: a base by market capitalisation (nano), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medicskin Holdings Ltd that is -6.8 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Medicskin Holdings Ltd (8307) delivered so far?
Over the past 5 years revenue at Medicskin Holdings Ltd grew +2.8 % a year. The price currently implies -6.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medicskin Holdings Ltd (8307) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Medicskin Holdings Ltd (-6.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medicskin Holdings Ltd (8307)?
The free-cash-flow yield on the price is 8.24 %: that much free cash flow Medicskin Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medicskin Holdings Ltd (8307)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medicskin Holdings Ltd it is HK$0.0500 per share (as of Sep 27, 2026), against a price of HK$0.1390. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Medicskin Holdings Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 8307 trades above its calculated fair value: price HK$0.1390, fair value HK$0.0500, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8307?
No. The price is what the market pays today (HK$0.1390); the fair value is what the company's own numbers justify (HK$0.0500). For Medicskin Holdings Ltd the two are HK$0.0890 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medicskin Holdings Ltd worth?
The market values Medicskin Holdings Ltd at about HK$69.8M (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.1390; our models calculate a fair value of HK$0.0500 per share.
What do the bullish and bearish scenarios say about 8307?
Our models span a range for Medicskin Holdings Ltd: cautious scenario HK$0.0400, base HK$0.0500, optimistic HK$0.0600 per share (as of Sep 27, 2026, price HK$0.1390). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medicskin Holdings Ltd (8307)?
Balance-sheet figures for Medicskin Holdings Ltd (as of Sep 27, 2026): return on equity 19.9%. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 8307 from its 52-week high?
Medicskin Holdings Ltd trades at HK$0.1390, about 31% below its 52-week high of HK$0.2000 and 36% above the low of HK$0.1020 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0500 is for.
Which stocks are comparable to Medicskin Holdings Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medicskin Holdings Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price HK$0.1390, calculated fair value HK$0.0500 (−64%), Quality Score 61/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8307 calculated?
We run Medicskin Holdings Ltd through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.0500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Medicskin Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medicskin Holdings Ltd (8307)?
The closing price on Sep 30, 2026 was HK$0.1390. Our model-based fair value is HK$0.0500, about −64% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medicskin Holdings Ltd right now?
The price sits above even our optimistic bull case (HK$0.0600). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Medicskin Holdings Ltd
How large is the market capitalisation of Medicskin Holdings Ltd (8307)?
The market capitalisation of Medicskin Holdings Ltd is HK$69.8M (≈ $8.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medicskin Holdings Ltd (8307)?
The price-to-sales ratio of Medicskin Holdings Ltd is 1.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Medicskin Holdings Ltd (8307)?
The net margin of Medicskin Holdings Ltd is 2.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medicskin Holdings Ltd (8307)?
The return on equity (ROE) of Medicskin Holdings Ltd is 19.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medicskin Holdings Ltd (8307)?
On an EBIT basis the return on assets of Medicskin Holdings Ltd is 4.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medicskin Holdings Ltd (8307)?
The operating margin of Medicskin Holdings Ltd is 3.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medicskin Holdings Ltd (8307)?
Revenue at Medicskin Holdings Ltd is growing +8.0% versus a year earlier (3y avg +1.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medicskin Holdings Ltd (8307)?
Earnings per share at Medicskin Holdings Ltd are growing −77.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Medicskin Holdings Ltd (8307) carry?
The net debt of Medicskin Holdings Ltd is HK$6.0M (fiscal year 2026, ≈ 1.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medicskin Holdings Ltd in the live analysis
One click puts Medicskin Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
